Education
About Us
Working with TipRanks
Follow Us
Cooper Companies (COO)
NASDAQ:COO
COO Stock Chart & Stats
$81.98
-$0.81(-0.88%)
At close: 4:00 PM EST
$81.98
-$0.81(-0.88%)
Day’s Range― - ―
52-Week Range$61.78 - $91.60
Previous CloseN/A
Volume244.93K
Average Volume (3M)1.72M
Market Cap
$16.34B
Enterprise Value$18.97B
Total Cash (Recent Filing)$110.60M
Total Debt (Recent Filing)$2.78B
Price to Earnings (P/E)44.5
Beta0.70
Next Earnings
Mar 05, 2026EPS Estimate
1.03Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.15
Shares Outstanding195,978,030
10 Day Avg. Volume1,709,227
30 Day Avg. Volume1,715,815
Financial Highlights & Ratios
PEG Ratio-8.16
Price to Book (P/B)1.70
Price to Sales (P/S)3.42
P/FCF Ratio32.24
Enterprise Value/Market Cap1.16
Enterprise Value/Revenue4.64
Enterprise Value/Gross Profit7.21
Enterprise Value/Ebitda18.61
Forecast
1Y Price Target
$89.92Price Target Upside9.69% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering14
EPS Forecast (FY)4.52
Revenue Forecast (FY)$4.32B
Bulls Say, Bears Say
Bulls Say
Corporate Strategic ReviewBoard appointment of a new chair and a formal strategic review that includes potential separation or divestiture of business units increase the likelihood of actions designed to unlock shareholder value.
Cost Savings And Free Cash FlowManagement expects pretax integration savings of $50 million in the current fiscal year, supporting margin improvement and reinforcing upward free cash flow trajectory that underpins analyst Buy ratings.
Product DifferentiationMiudella's shorter labeled duration and nickel-containing nitinol frame restrict its appeal for long-duration users and for patients with nickel allergy, which limits its addressable market relative to Paragard and helps preserve Paragard's core patient base.
Bears Say
Clinical Study And Labeling RiskIf competitor clinical data supports a longer-term label, uptake of the rival device could broaden beyond niche use and materially increase competitive pressure on Paragard.
Licensing-driven CompetitionOrganon's acquisition of global commercial rights to a non-hormonal intrauterine device creates a new, well-supported rival that raises competitive pressure on Paragard's market share.
Physician Adoption In Specific SegmentsSome clinicians preferring a shorter-duration option or treating patients with smaller uteruses may choose the rival device, creating targeted share loss for Paragard in those patient segments.
Cooper Co News
COO FAQ
What was Cooper Companies’s price range in the past 12 months?
Cooper Companies lowest stock price was $61.77 and its highest was $91.60 in the past 12 months.
What is Cooper Companies’s market cap?
Cooper Companies’s market cap is $16.34B.
When is Cooper Companies’s upcoming earnings report date?
Cooper Companies’s upcoming earnings report date is Mar 05, 2026 which is today.
How were Cooper Companies’s earnings last quarter?
Cooper Companies released its earnings results on Dec 04, 2025. The company reported $1.15 earnings per share for the quarter, beating the consensus estimate of $1.113 by $0.037.
Is Cooper Companies overvalued?
According to Wall Street analysts Cooper Companies’s price is currently Undervalued.
Does Cooper Companies pay dividends?
Cooper Companies pays a Semiannually dividend of $0.007 which represents an annual dividend yield of N/A. See more information on Cooper Companies dividends here
What is Cooper Companies’s EPS estimate?
Cooper Companies’s EPS estimate is 1.03.
How many shares outstanding does Cooper Companies have?
Cooper Companies has 195,978,030 shares outstanding.
What happened to Cooper Companies’s price movement after its last earnings report?
Cooper Companies reported an EPS of $1.15 in its last earnings report, beating expectations of $1.113. Following the earnings report the stock price went up 5.673%.
Which hedge fund is a major shareholder of Cooper Companies?
Currently, no hedge funds are holding shares in COO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Cooper Co Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$89.92 (9.69% Upside)
$89.92 (9.69% Upside)
Blogger Sentiment
Bullish
COO Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 6.1M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $1.3M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▲ 0.4%
Last 30 Days ▼ 0.4%
Last 30 Days ▼ 0.4%
News Sentiment
Bullish
Bullish news 79%
Bearish news 17%
Bearish news 17%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-9.58%
12-Months-Change
Fundamentals
Return on Equity
4.59%
Trailing 12-Months
Asset Growth
0.65%
Trailing 12-Months
Company Description
Cooper Companies
The Cooper Companies, Inc., together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment offers spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, myopia, ocular dryness and eye fatigues in the Americas, Europe, Middle East, Africa, and Asia Pacific. The CooperSurgical segment focuses on family and women's health care, which provides medical devices, fertility, genomics, diagnostics, and contraception to health care professionals and patients worldwide. It offers surgical and office products, including PARAGARD, uterine manipulators, retractors, closure products, point of care products, LEEP products, endosee, and illuminate and fetal pillows; fertility products and services, such as fertility consumables and equipment, and embryo options and preimplantation genetic testing. The Cooper Companies, Inc. was founded in 1958 and is headquartered in San Ramon, California.
COO Company Deck
COO Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The company's earnings call reflected a focus on strong financial performance and strategic growth initiatives. While CooperVision and the share repurchase program showed significant positive trends, challenges in certain markets, particularly in China and the fertility segment, posed some concerns.View all COO earnings summariesCOO Net sales Breakdown
67.05% CooperVision
32.95% CooperSurgical
COO Stock 12 Month Forecast
Average Price Target
$89.92
▲(9.69% Upside)
Technical Analysis
Ownership Overview
0.57% Insiders
36.86% Mutual Funds
23.75% Other Institutional Investors
13.23% Public Companies and
Individual Investors